Bronwyn Brophy has over 25 years’ experience in the MedTech industry having also worked for Thermo Fisher Scientific, Medtronic, Covidien, and Johnson & Johnson in a number of senior roles around the globe covering businesses including general surgery, women’s health, gastroenterology, cardiology and oncology. She is now the CEO of the Vitrolife Group, a world leading provider of medical devices and genetic services for the reproductive health industry. The company is headquartered in Gothenburg, Sweden and is listed on the NASDAQ Stockholm. It has over 1100 employees and a revenue of circa $360M. Vitrolife is a world-leading global provider of medical devices and genetic testing services. Dedicated to the reproductive-health market since 1994, they have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry. A global leader in reproductive health focused on supporting customers and patients worldwide to improve treatment outcomes – always with sustainability in mind. Based on science and advanced research capabilities, their aim is to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality. She has a strong track record in strategy development, accelerating profitable growth, leading M & A and also driving digital transformations. Bronwyn has led several large scale R & D programs, building out next generation platforms. She has worked in multiple regions globally and has experience driving geographic expansion in the U.S. and China. This is the 44th episode with guest Bronwyn Brophy, CEO of the Vitrolife Group, in the Davy podcast series 'Everyday Business with Aidan Donnelly'.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related